AstraZeneca PLC:
* ASTRAZENECA PLC - ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC
* ASTRAZENECA - ENHERTU GRANTED PRIORITY REVIEW IN US FOR PATIENTS WITH HER2-LOW METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}